Navigation Links
Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
Date:4/8/2008

he improvements were achieved without any limiting next day cognitive effects. In both the Phase 1 program and the Phase 2a trial, APD125 was well tolerated at all doses investigated.

About APD125

Discovered by Arena, APD125 is a novel and oral selective inverse agonist of the 5-HT2A serotonin receptor. The vast majority of approved drugs for insomnia activate the GABA-A receptor complex in the brain, causing a general suppressive effect on the central nervous system, or CNS. These GABAergic drugs are generally associated with CNS side effects, including a sensation of dullness and lethargy upon awakening, often referred to as the "hangover effect." Other potential problems associated with the GABAergic drugs include the risk of developing tolerance and drug dependency in at-risk populations. In addition, GABAergic drugs are scheduled controlled substances by the Drug Enforcement Administration due to their potential for abuse.

By selectively targeting the 5-HT2A receptor, APD125 acts through a different mechanism than currently marketed insomnia drugs and blocks one of several CNS activating pathways. Because of the different mechanism of action, APD125 may not have the side effects or abuse potential generally associated with currently approved GABAergic drugs. Through its novel mechanism, APD125 has the potential to reduce insomnia symptoms by improving sleep maintenance.

About Insomnia

Insomnia is characterized by inadequate or poor sleep due to nonrefreshing sleep, frequent wakening with difficulty falling back to sleep, difficulty falling asleep or waking too early. Most insomnia complaints relate to sleep maintenance issues, such as waking frequently or awakening too early, as opposed to problems with sleep latency (i.e. falling asleep). About 30% of US adults report some level of insomnia in the course of a year, and about 10% of US adults indicate that their condition is chronic. In these cases, the lack of restful sleep i
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
2. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 22, 2014 WHEN: Wednesday, October 29, 2014 ... available at: http://bit.ly/1yStiU9 SPEAKERS: Visionary ... Visionary Innovation Research Group Senior Research Analyst ... materials, nanobots and flexible electronics are among ... our lives in the coming decades. These ...
(Date:10/22/2014)... -- Recently published clinical studies of Stretta for gastroesophageal reflux ... evidence. This data has led to significantly expanded insurance ... sufferers of refractory GERD. The substantial ... as a safe and effective GERD treatment has driven ... nearly 50 million Americans. The new clinical studies include; ...
(Date:10/20/2014)... MOUNTAIN VIEW, California , 20 de octubre ... un líder en el campo de la pulmonología ... en su Estudio RENEW, casi 3 meses antes ... prueba fundamental de exención de dispositivo de investigación ... y Medicamentos) para el sistema de espiral de ...
Breaking Medicine Technology:Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4Recent Clinical Study Data Confirms Efficacy of Stretta Therapy - Spurs Additional Insurance Coverage and Financing Round 2PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3
... , , 1. Visit ... Visit your local doctor one month prior to your intended trip departure date. ... , , ... , Discuss with your doctor or a Travellers ...
... JERUSALEM , June 2, 2010 ... systems, announced,today that its subsidiary Oramed Ltd. entered into a ... Israeli company listed on,the Tel Aviv Stock Exchange, for the ... ("Entera"). Under the terms of the agreement, Oramed,will out-license technology ...
Cached Medicine Technology:Medical Tips for Traveling to the 2010 World Cup from WorldNomads.com 2Medical Tips for Traveling to the 2010 World Cup from WorldNomads.com 3Medical Tips for Traveling to the 2010 World Cup from WorldNomads.com 4Oramed Pharmaceuticals Forms Joint Venture - Launches Entera Bio Ltd. 2Oramed Pharmaceuticals Forms Joint Venture - Launches Entera Bio Ltd. 3
(Date:10/22/2014)... 22, 2014 Isabel Healthcare ... Health Professions (ASAHP) Conference on October 22-24 in Las ... participate in a panel discussion on Technology in Health ... Healthcare provides a diagnostic decision support tool and clinical ... skills of students and clinical learners. The Isabel tools ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 The ... , which is dedicated to distribute health information ... healthcare delivery worldwide announced the development of six ... patients expect when receiving healthcare. These are an ... patient-centered care: “providing care that is respectful of ...
(Date:10/22/2014)... Healthcare professionals who are looking for ... home or on-the-go via laptops, tablets or mobile ... premium Seminar-on-Demand CE courses. The new courses add ... hours of CE course offerings, allowing therapy ... such a diverse library, there’s something for everyone. ...
(Date:10/22/2014)... 2014 Akeso Biomedical, Inc. , ... treatment of bacterial infections, microbial biofilms, and chronic wounds, ... board of directors. , Dr. Sinskey ... The Massachusetts Institute of Technology, or MIT. He has ... Dr. Sinskey also holds positions as Co-Director of the ...
(Date:10/22/2014)... By Maureen Salamon ... -- A crucial part of conventional in vitro fertilization (IVF) ... can instead take place in a device inside the vagina, ... Colombia contend that the device, called an INVOcell, might sharply ... could also make the technology more accessible to those who ...
Breaking Medicine News(10 mins):Health News:Isabel Healthcare to Participate in The Association of Schools of Allied Health Professions (ASAHP) 2014 Conference 2Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4
... of world,s biological manufacturing capacity is in Puerto Rico, ... the world,s,biotechnology manufacturing capacity is located in Puerto Rico, ... Over the past four years, more than $4 ... such giants as Eli Lilly, Amgen, Abbot,Ortho Biologics, BD ...
... jobs that require them to be physically active may be ... be at a decreased risk of developing prostate cancer, according ... studied more than 2,100 men who worked at the Rocketdyne ... exposed to radiation and chemicals that may have increased their ...
... Feb. 12 /PRNewswire-FirstCall/ - Predictive medicine company,PreMD Inc. (TSX: ... company,s,business direction in light of the recent decision from ... the FDA, PreMD today filed a request for ... with the following Code of Federal Regulations 21,CFR part ...
... Brings Significant Healthcare Leadership Experience to CTG,s Board, ... ), an,international information technology (IT) staffing and solutions company,today ... McGuire, a,healthcare executive who has served as CEO of ... a Director of CTG. Most recently,Mr. McGuire served from ...
... N.J., Feb. 12 TeamStaff, Inc.,(Nasdaq: ... and administrative,staffing services, announced today that it ... division, RS Staffing Services, Inc., to TeamStaff,Government ... Georgia based subsidiary currently provides medical, office,administration ...
... YUCAIPA, Calif., Feb. 12 Ingen Technologies,Inc. (OTC ... the signed distribution agreement with Progressive International,Holding Co. ... Taiwan, People,s,Republic of China, Japan and Korea. Please ... Progressive International Holding Company (PIHK),( http://www.pgiholding.com ) and ...
Cached Medicine News:Health News:Opportunities to Invest in Puerto Rico as Global Center for Biotechnology 2Health News:Men who are continually active at work may have a decreased risk of prostate cancer 2Health News:Men who are continually active at work may have a decreased risk of prostate cancer 3Health News:PreMD Initiates FDA Review Process and Provides Corporate Update 2Health News:PreMD Initiates FDA Review Process and Provides Corporate Update 3Health News:CTG Names William D. McGuire a Director 2Health News:CTG Names William D. McGuire a Director 3Health News:TeamStaff Renames Subsidiary to Reflect Expanding Government Services 2Health News:TeamStaff Renames Subsidiary to Reflect Expanding Government Services 3Health News:Ingen Technologies Brings Oxyview(R) to Asia Through Major Medical Distributor 2Health News:Ingen Technologies Brings Oxyview(R) to Asia Through Major Medical Distributor 3
... unique microprocessor controlled shaking incubator that accommodates ... or 384 well format. Speed, temperature and ... and all are displayed on the LCD. ... protective cover. The Millennium 2000 can be ...
Microplate incubator shaker used in a variety of immunoassay and research procedures requiring microplates....
... FACSCalibur is the only four-color, automated ... both analysis and cell sorting. Designed specifically ... the FACSCalibur system offers software instrument control, ... maximum ease and productivity. FACSCalibur is fully ...
Multiparameter laser and arc lamp flow cytometer for all applications in immunology, microbiology, cell biology, pathology, hematology, lymphocyte dubset and cell analysis....
Medicine Products: